[PDF][PDF] Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate
PA Meyers, CL Schwartz, M Krailo… - Journal of clinical …, 2005 - researchgate.net
PA Meyers, CL Schwartz, M Krailo, ES Kleinerman, D Betcher, ML Bernstein, E Conrad…
Journal of clinical oncology, 2005•researchgate.netPurpose To determine whether the addition of ifosfamide and/or muramyl tripeptide (MTP)
encapsulated in liposomes to cisplatin, doxorubicin, and high-dose methotrexate (HDMTX)
could improve the probability for event-free survival (EFS) in newly diagnosed patients with
osteosarcoma (OS).
encapsulated in liposomes to cisplatin, doxorubicin, and high-dose methotrexate (HDMTX)
could improve the probability for event-free survival (EFS) in newly diagnosed patients with
osteosarcoma (OS).
Purpose
To determine whether the addition of ifosfamide and/or muramyl tripeptide (MTP) encapsulated in liposomes to cisplatin, doxorubicin, and high-dose methotrexate (HDMTX) could improve the probability for event-free survival (EFS) in newly diagnosed patients with osteosarcoma (OS).
researchgate.net